Clovis Oncology Inc (NASDAQ:CLVS)

3.15
Delayed Data
As of Nov 30
 +0.06 / +1.94%
Today’s Change
3.02
Today|||52-Week Range
11.10
-34.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$419.2M

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Information

Clovis Oncology, Inc.
5500 Flatiron Parkway
Boulder Colorado 80301
P:(303) 625-5000
Investor Relations:
(303) 625-5023

Employees

Shareholders

Mutual fund holders30.22%
Individual stakeholders3.71%
Other institutional22.13%

Top Executives

Patrick J. MahaffyPresident, Chief Executive Officer & Director
Daniel W. MuehlChief Financial Officer & Executive Vice President
Lindsey RolfeChief Medical Officer & Executive VP-Clinical
Thomas Fuglsang HardingChief Scientific Officer & Executive VP
Gillian C. Ivers-ReadChief Regulatory Officer & Executive VP